Introduction {#S1}
============

Diabetes mellitus (DM) is one of the common clinical diseases in the world. It is a group of metabolic diseases characterized by chronic hyperglycemia and one of the most important chronic non-communicable diseases. The prevalence of DM in adults aged 18 years and older is 11.6%, and the majority of them are type 2 diabetes mellitus (T2DM) ([@B20]; [@B17]; [@B32]). Due to the acceleration of urbanization, an aging population, the change in lifestyle (significant reduction in physical activity, the marked increasing in the proportion of fat intake, and the increasingly fast the pace of life), the increase in the proportion of obesity, overweight, and other factors, the prevalence of DM may be higher and higher, and there are more patients with DM; DM has a higher morbidity and mortality, and is an independent risk of atherosclerotic vascular disease. It is one of the factors that have brought a serious burden on the health of individuals and society ([@B7]; [@B31]; [@B9]). Prevention and treatment of DM is the main solution to reduce mortality, disability and improve quality of life. With the application of hypoglycemic drugs, the popularization of blood glucose monitoring methods, the control of complications of DM, and lifestyle interventions, DM has achieved certain prevention and treatment. As a result, its direct mortality rate has declined; however, due to the limited epidemiological survey status, the high proportion of undiagnosed population, and a large number of DM high-risk groups ([@B31]; [@B10]; [@B9]), the prevention and treatment of DM has yet to be further studied. Recent studies have shown that RNA (microRNA, miRNA) is closely related to the pathogenesis of DM, and miRNA-126, miRNA-28-3p, and miRNA-423-5p may be involved in the pathogenesis of DM ([@B15]; [@B8]). MicroRNAs may be involved in the development of a variety of cardiovascular diseases, such as atherosclerosis, myocardial infarction, heart failure, hypertension, pulmonary hypertension, arrhythmia and cardiomyopathy, etc. ([@B4]; [@B5]; [@B1]); Some studies have also found some serum or plasma. The circulating miRNA can be used as a potential disease diagnostic biomarker for DM ([@B2]; [@B19]), providing new ideas and new methods for the prevention and treatment of DM. However, there are few clinical samples of plasma circulating miRNA-126, miRNA-28-3p and DM. Therefore, this paper intends to investigate the relationship between plasma circulatory miRNA-126, miRNA-28-3p and DM, and conduct related bioinformatics analysis in order to explore new ways for DM prevention and provide theoretical support.

Materials and Methods {#S2}
=====================

Clinical Data {#S2.SS1}
-------------

Patients were selected from September 2016 to May 2018 in the Department of Endocrinology, Internal Medicine Division, The Second Affiliated Hospital of Nanchang University.

Eighty patients with T2DM were included in the observation group (DM group), and 120 patients without DM who were hospitalized in the endocrinology department and the cardiology department were used as the control group. The diagnostic criteria of T2DM are diagnosed and classified using the criteria for DM diagnosis, glucose metabolism status classification, and DM classification system recommended in the "CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY." Patients with malignant tumors, acute infections and systemic immune diseases, thyroid diseases, various organ transplants, and severe heart, lung, liver, and renal insufficiency were excluded. Patients in the two groups were equal in age, sex, and body mass index. There was no statistically significant difference in the basic medical history of dex, BMI, smoking history, coronary heart disease, hypertension, and stroke (*P* \> 0.05); in conventional cardiovascular medications such as beta-blockers, calcium channel blocker (CCB).

There was no statistically significant difference between CCB, angiotensin converting enzyme inhibitor (ACEI), and angiotensin receptor blocker (ARB) (*P* \> 0.05); There was no significant difference in biochemical examination between TC and other patients (*P* \> 0.05), such as serum creatinine (Scr), blood urea nitrogen (BUN), glucose (Glu), total cholesterol (TC), and total cholesterol (total cholesterol). The average age of DM patients in the DM group was 5.246 years. The average fasting blood glucose was 12.02 mmol/L, and the postprandial blood glucose was 15.66 mmol/L in average; the difference between serum uric acid (SUA), lipoprotein (a), lipoprotein (a), Lp (a), high density lipoprotein, and HDL was not statistically significant (*P* \> 0.05). The low-density lipoprotein (LDL) in the control group was slightly higher than that in the DM group (*P* \< 0.05), as shown in [Table 1](#T1){ref-type="table"}.

###### 

Basic medical history and biochemical examination of two groups of patients (*n* = 120).

  Item                                  DM group         control group    *P*
  ------------------------------------- ---------------- ---------------- --------
  Age (years)                           67.81 ± 1.11     64.95 ± 1.19     0.0797
  Sex (male/female, case)               43/37            45/35            0.7506
  BMI (kg/m^2^)                         23.00 ± 0.20     25.35 ± 2.20     0.2978
  History of smoking (case)             35               37               0.7506
  Coronary heart disease (case)         25               28               0.6143
  Hypertension (case)                   34               37               0.6473
  Atrial fibrillation (case)            17               15               0.6926
  Stroke (case)                         16               13               0.5381
  β-receptor blockers (case)            35               36               0.8736
  CCB (case)                            30               22               0.4933
  ACEI (case)                           25               27               0.8661
  ARB (case)                            28               22               0.3939
  SUA (μmol/L)                          328.22 ± 10.92   314.12 ± 13.47   0.4126
  SCR (μmol/L)                          89.00 ± 6.42     96.40 ± 12.64    0.6022
  Duration of DM in patients (years)    5.25 ± 1.91      --               --
  Maximum fasting glucose (mmol/L)      12.02 ± 0.60     --               --
  Postprandial blood glucose (mmol/L)   15.66 ± 0.71     --               --
  Glu (mmol/L)                          5.56 ± 0.21      5.99 ± 0.16      0.1029
  Lp(a) (mmol/L)                        204.82 ± 17.89   183.43 ± 17.67   0.3993
  BUN (mmol/L)                          4.90 ± 0.23      8.88 ± 2.92      0.1754
  TC (mmol/L)                           4.90 ± 0.12      5.14 ± 0.17      0.2400
  TG (mmol/L)                           1.55 ± 0.08      1.43 ± 0.11      0.3630
  HDL (mmol/L)                          1.43 ± 0.04      1.35 ± 0.04      0.1443
  LDL (mmol/L)                          2.75 ± 0.11      3.09 ± 0.14      0.0485

Sample Collection {#S2.SS2}
-----------------

All selected patients provided 2 mL of venous blood with EDTA anticoagulant tubes within 4 h of admission, and then centrifuged (2500 r/min, 4°C, 10 min) in 2 h to separate plasma and dispensed in 1.5 mL EP tubes. Stored in a refrigerator at 120°C for follow-up experiments; collected basic medical history, medications for cardiovascular disease, and basic biochemical tests.

Plasma miRNA-126 and miRNA-28-3p Real-Time Fluorescent Quantitative Detection {#S2.SS3}
-----------------------------------------------------------------------------

The miRNA was extracted and purified by column isolation using miRNAcute miRNA Extraction and Separation Kit (Shanghai MiTuo Biotechnology Co., Ltd.), and then miRNA was reverse-transcribed to cDNA according to its companion miRNAcute miRNA cDNA first-strand synthesis kit (Shanghai MiTuo Biotechnology Co., Ltd.). Finally, fluorescence quantitative detection was performed according to the miRNAcute miRNA SYBR Green Fluorescent Quantitative Detection Kit (Guangzhou Zhenzhi Biotech Co., Ltd.) and downstream primers in the kit. hsa-miR-126-3p (hsa-miR-126, MIMAT0000445 UCGUACCG UGAGUAAUAAUGCG), hsa-miR-28-3p (MIMAT0004502 CACUAGAUUGUGAGCUC-CUGGA).

The upstream primers and internal reference U6 primers of hsa-miR-126-3p and hsa-miR-28-3p were provided by Shanghai MiTuo Biotechnology Co., Ltd. (shanghai, China). The downstream primers were universal primers for the kit. All procedures were performed according to the kit instructions. The fluorescence quantification procedure was performed at 94°C for 2 min; the template was denatured at 94°C for 20 s in the PCR cycle; annealing was performed at 60°C for 34 s; a total of 30 cycles. In this study, 2 -- ΔCt relative quantification method was used for data analysis: ΔCt (experimental group) = Ct (experimental group target gene) − Ct (experimental group reference gene); ΔCt (control group) = Ct (control group target gene) - Ct (control group internal reference).

miRNA-126 and miRNA-28-3p Bioinformatics Prediction {#S2.SS4}
---------------------------------------------------

Target bioinformatics software such as targetScan, GCBI online website, [microRNA.org](http://www.microrna.org/microrna/home.do), and miRanda was used to predict the target genes of miRNA-126 and miRNA-28-3p; KEGG pathway and starBase were used to predict the basic bioinformatics function, the signaling pathways that may be involved in regulation, the related circular RNAs (circular RNA, circRNA) and long non-coding (lncRNA), etc. ([@B13]), and analyzed and mapped the results using CircNet software ([@B14]); Using miRNAMap2 to predict miRNA-126 and miRNA-28-3p expression levels of various organs ([@B11]); UCSC Genome Browser was used to predict introns, exons and polymorphic sites of miRNA-126 and miRNA-28-3p ([@B18]; [@B24]).

RT-qPCR Detection of the Target Genes in Plasma {#S2.SS5}
-----------------------------------------------

RT-qPCR was used to verify the expression level of the most relevant five target genes regulated respectively by miRNA-126 and miRNA-28-3p in serum. The primers for the top five most relevant target genes regulated by miRNA-126 and miRNA-28-3p, respectively, are shown in [Table 2](#T2){ref-type="table"} (Primers were synthesized according to the PCR primer information provided by the Primer Bank database). The real-time PCR kit was used to detect the expression of these genes and to draw statistical charts. The reaction procedure was: Hol d (pre-denaturation): 95°C, 30 s, 1 cycle; Two-step PCR: 95°C, 5 s, 60°C, 30 s, 40 cycles; Dissociation: 95°C, 15 s, 60°C, 30 s, 95°C, 15 s, 1 cycle. GAPDH was used as an internal reference and a two-step method was used. The expression of GAPDH was detected by qPCR. Using the expression level of GAPDH as the standard value "1," the relative expression levels of each target gene in the plasma of DM and control group were calculated.

###### 

The primers for the top five most relevant target genes regulated by miRNA-126 and miRNA-28-3p, respectively.

           Sequence (5′--\>3′)                             Amplicon Size   Corresponding microRNA
  -------- --------------------- ------------------------- --------------- ------------------------
  VEGFA    Forward               AGGGCAGAATCATCACGAAGT     75              miRNA-126
           Reverse               AGGGTCTCGATTGGATGGCA                      
  SPRED1   Forward               GAGGGAGTGGACTAAGCAGC      241             miRNA-126
           Reverse               CCTCTATCAAAAGCCCTAGCATC                   
  PIK3R2   Forward               AAAGGCGGGAACAATAAGCTG     85              miRNA-126
           Reverse               CAACGGAGCAGAAGGTGAGTG                     
  PARP16   Forward               CCTCAAAGGTCCTGACAATCC     198             miRNA-126
           Reverse               CTAGGCGGCTACCATGAAATG                     
  SLC7A5   Forward               GGAAGGGTGATGTGTCCAATC     83              miRNA-126
           Reverse               TAATGCCAGCACAATGTTCCC                     
  IGF1     Forward               GCTCTTCAGTTCGTGTGTGGA     133             miRNA-28-3p
           Reverse               GCCTCCTTAGATCACAGCTCC                     
  IGF2R    Forward               GTGACCAGCAAGGCACAAATC     245             miRNA-28-3p
           Reverse               CACCAAGTAGGCACCACTAAG                     
  MAP2K3   Forward               GAGGGAGACGTGTGGATCTG      129             miRNA-28-3p
           Reverse               CCGCACGATAGACACAGCAAT                     
  MAPK1    Forward               TCTGGAGCAGTATTACGACCC     134             miRNA-28-3p
           Reverse               CTGGCTGGAATCTAGCAGTCT                     
  RAF1     Forward               GGGAGCTTGGAAGACGATCAG     165             miRNA-28-3p
           Reverse               ACACGGATAGTGTTGCTTGTC                     

Statistical Analysis {#S2.SS6}
--------------------

Data in GraphPad Prism 7 (GraphPad Software Inc., CA, United States) and IBM SPSS 17.00 (IBM Analytics, United States) were used for analysis. Qualitative data were analyzed using χ^2^-test or Fisher test. Measured data were expressed as mean ± standard deviation (x ± s) and data were compared using t test. The receiver operating characteristic curve (ROC curve) and ROC analysis were completed by GraphPad Prism 5. *P* \< 0.05 was defined as statistically significant, *P* \< 0.01 was defined as very significant statistical significance.

Results {#S3}
=======

Expression of Plasma miRNA-126 and miRNA-28-3p {#S3.SS1}
----------------------------------------------

After real-time fluorescence quantitative analysis of plasma miRNAs in two groups of patients, the expression level of miRNA-126 in plasma of DM patients (0.1162 ± 0.0236) was found to be higher than that of control patients (0.0018 ± 0.0862) and the difference was statistically significant (*P* \< 0.01); the expression of miRNA-126 in the plasma of the DM group was \~60 times than that of the control group ([Figure 1A](#F1){ref-type="fig"}). The expression level of miRNA-28-3p in the plasma of DM patients (0.1378 ± 0.0268) was higher than that in the control group (0.0006 ± 0.0167) and the difference was statistically significant (*P* \< 0.01).

![**(A)** Real-time fluorescence quantitative results of miRNA-126. **(B)** Real-time fluorescence quantitative results of miRNA-28-3p. **(C)** miRNA-126 and miRNA-28-3p correlation analysis. ^∗^*p* \< 0.05.](fgene-11-00367-g001){#F1}

The expression of miRNA-28-3 in plasma of DM group was \~230 times in the control group ([Figure 1B](#F1){ref-type="fig"}). Correlation analysis revealed a positive correlation between miRNA-126 and miRNA-28-3p ([Figure 1C](#F1){ref-type="fig"}), with a Pearson correlation coefficient of 0.4337 and a 95% confidence interval (CI) of \[0.2984, 0.5516\] (*P* \< 0.01).

ROC Curve Analysis of miRNA-126 and miRNA-28-3p {#S3.SS2}
-----------------------------------------------

The ROC curve analysis of miRNA-126 and miRNA-28-3p in plasma of the two groups of patients revealed that the area under the curve (AUC) of miRNA-126 in DM patients was 0.9989. The 95% CI was \[0.984, 1.000\], and there was a significant difference between the control group and the control group (*P* \< 0.01). The miRNA-126 ROC curve is shown in [Figure 2A](#F2){ref-type="fig"}, with a cut-off of 0.01124, a sensitivity of 96.35% (89.43--99.22%), and a specificity of 98.95% (93.23--99.97%); AUC of miRNA-28-3p ROC in DM patients was 0.9979, 95% CI was \[0.9736, 1.000\], which was significantly different from the control group (*P* \< 0.01). Its ROC curve is shown in [Figure 2B](#F2){ref-type="fig"}, with a cut-off value of 0.0020, a sensitivity of 99.35% (93.23--99.97%), and a specificity of 98.75% (91.26--99.70%).

![**(A)** ROC curve of miRNA-126 expression in plasma. **(B)** ROC curve of miRNA-28-3p expression in plasma.](fgene-11-00367-g002){#F2}

miRNA-126 and miRNA-28-3p Bioinformatics Analysis Results {#S3.SS3}
---------------------------------------------------------

Through bioinformatics analysis of multiple softwares, the target genes of miRNA-126 were found to be: VEGFA, SPRED1, PIK3R2, PARP16, TNFRSF11B, ADAM9, SLC7A5, and AKAP13; its biological functions are mainly associated with binding proteins, signal transduction, cell differentiation and regulation of cell morphology, etc.; its main role in regulating signaling pathways are: MAPK activation pathway, insulin receptor signaling pathway, insulin signaling pathway, chemokine signaling pathway, connexin signaling (Jak-STAT) pathways, and angiogenesis signal pathways. The target genes of miRNA-28-3p mainly include IGF1, IGF2R, MAP2K3, MAPK1, RAF1, RASA1, COIL, PSAP, CSNK1G1, MTHFD2L, C4orf52, BIRC5, SGK269, AP3M1, IKBKB, SLC9A8, MAPK1, DRAM1, CDKN1A, SRPK1, and BCL2L11, etc.; its biological functions are mainly related to cell proliferation, apoptosis, cell migration, signal transduction, glucose protein binding and fatty acid oxidative metabolism. Biological functions involved in the regulation of signaling pathways include: MAPK signaling pathway ([Figure 3](#F3){ref-type="fig"}), insulin/IGF signaling pathway ([Figure 4](#F4){ref-type="fig"}), endothelin signaling pathway, TGF-beta signaling pathway ([Figure 5](#F5){ref-type="fig"}) and ngiogenesis signaling pathways ([Figure 6](#F6){ref-type="fig"}).

![miRNA-28-3p promotes cell proliferation through the MAPK signaling pathway and participates in the regulation of diabetes.](fgene-11-00367-g003){#F3}

![miRNA-28-3p promotes cell proliferation and migration through the IGF signaling pathway and participates in the regulation of diabetes.](fgene-11-00367-g004){#F4}

![miRNA promotes signal transduction and glucose protein binding through the TGF-beta signaling pathway and participates in the regulation of diabetes.](fgene-11-00367-g005){#F5}

![miRNA regulates cell proliferation and apoptosis via the Angiogenesis signaling pathway and participates in angiogenesis in diabetes.](fgene-11-00367-g006){#F6}

By analyzing the sequence structure of miRNA-126 and miRNA-28-3p, and predicting possible lncRNA and circRNA, it was found that the lncRNA related to miR-126 was XIST, and the circRNA was PLXNB2_hsa_circ_000681; the lncRNAs associated with miRNA-28-3p were RP11-197N18. 2, CTC-338M12. 3, OIP5-AS1, MMP24-AS1, RP11169K16. 9, CTD-2116N17. 1, RP11-815I9. RP11-384K6. 6, PLK1S1, AJ271736. 10, LOXL1-AS1, CTD-3014M21. 4, AC092535. 3, RP11-615I2. 7, RP4-647J21. 1, and XIST, and their related circRNA were ARL6IP4 \_hsa_circ_000812, ITPR1 \_ hsa \_ circ \_000705, C5orf25 \_hsa_circ_001525, KIF2A_hsa_circ_001171, FKBP8_hsa_circ\_ 000270, KDM3B_hsa_circ_001423, KIAA1586_hsa\_ circ_0014 39, GBAS_hsa_circ_002070, STIM2_hsa_circ_001520, KPNB1\_ hsa_circ_002147, HIST1H3D_hsa_circ_000744, CPNE1_hsa\_ circ_000657, TIMELESS_hsa_circ_002140, FAM188A_hsa_circ\_ 001836, FAM188A_hsa_circ_001349, FARSA_hsa_circ_000263, YLPM1_hsa_circ_001060 and CHEK2 \_hsa_circ_001796, etc. Analysis of the relevant target genes and circRNAs revealed that complex genes and circRNAs are involved in the regulation ([Figure 7](#F7){ref-type="fig"}). The interaction mechanism between miRNAs and circRNAs has been studied.

![**(A)** Regulatory map of miRNA-126 related genes. **(B)** Regulatory map of miRNA-28-3p and related genes.](fgene-11-00367-g007){#F7}

Current studies suggest that circRNAs may be mainly used as "sponge" adsorption. They play a role in competitively inhibiting miRNA target genes, and we have discovered through software analysis a variety of miRNA126 and miRNA-28-3p sponge circRNAs and genes ([Figure 8](#F8){ref-type="fig"}). At the same time, miRNA expression may have cell, tissue and organ specificity. We have found that miRNA-126 and miRNA-28-3p have relative expression in various organs through software enrichment analysis: miRNA-126 was found to be highly expressed in lung tissue, muscle tissue, and uterus, but was lower in liver and trachea tissues; miRNA-28-3p was expressed higher in the bladder, prostate, muscle, and uterus, but lower in liver, fat, and brain tissue ([Figure 9](#F9){ref-type="fig"}). Researches on miRNAs did not simply remain at the level of miRNA expression. Most studies have performed in-depth functional studies, such as miRNA introns, exons, 3′-UTR, and related region polymorphism sites (SNPs). In other areas of research, we have found bioinformatics functional site distributions of miRNA-126 and miRNA-28-3p through bioinformatics analysis: the miRNA-126 functional region is mainly located on the EGFL7 and ve-statin genes on chromosome 9q12. Nearby, there are multiple SNP sites; miRNA-28-3p is mainly located near the LPP gene and has multiple SNP sites.

![**(A)** miRNA-126 with associated "sponge" genes and circRNA. **(B)** miRNA-28-3p with associated "sponge" genes and circRNA.](fgene-11-00367-g008){#F8}

![Organ specific expression of miRNA-126 and miRNA-28-3p.](fgene-11-00367-g009){#F9}

Real-Time qPCR Verification of Target Genes {#S3.SS4}
-------------------------------------------

Results of real-time quantitative PCR detection of differentially expressed genes were listed in [Figure 10](#F10){ref-type="fig"}, the relative expression of each target gene in the figure was calculated according to the relative expression quantity = 2 -- ΔCT formula, where ΔCT = CT value of target gene -- CT value of internal reference gene (GAPDH). As can be seen from the figure, the expression level of all target genes in DM group was significantly lower than that in control group ([Figure 10](#F10){ref-type="fig"}).

![**(A)** The relative expression levels of the most relevant 5 target genes regulated by miRNA-126 in the plasma of DM and control group. **(B)** The relative expression levels of the most relevant 5 target genes regulated by miRNA-28-3p in the plasma of DM and control group.](fgene-11-00367-g010){#F10}

Discussion {#S4}
==========

The number of people with DM in the world is large, and the population with high risk factors for DM has a large base. The prevention and treatment of DM are facing major challenges. In recent years, research on the pathogenesis of DM and miRNA has become a hot topic. Some miRNAs have also been found to be closely related to the pathogenesis of DM, especially in recent years, the discovery of cyclic miRNA and the maturity of its detection technology have opened up new avenues for DM research ([@B25]; [@B22]). Extensive exonuclease is present in serum or plasma. Unmodified miRNAs are rapidly degraded in serum of plasma patients, and the stability of circulating miRNAs in serum or plasma is high, and they have strong ability against ribonuclease, so its detection has stronger reliability ([@B3]; [@B19]). [@B28] found that the expression of miRNA-296 in plasma of DM patients was correlated with the plasma leptin level, while the expression of miRNA-9 was correlated with insulin levels; [@B30] found that differentially expressed miRNAs in the plasma of DM and DM pre-patients, such as miRNA-1249, miRNA-320b, miRNA-572, and miRNA-6069, may be new biomarkers for early diagnosis of DM and potential therapeutic targets; [@B27] conducted a study of Iranian and Swedish populations which found that plasma miRNA-93, miRNA-103, miRNA-191, miRNA-423-3p, miR-NA-425, and miRNA451 were all differentially expressed in DM patients and expressed in different populations. The situation is inconsistent; [@B21] found that both miRNA-15b and miRNA-376a may be involved in the pathogenesis of DM, and serum miRNA-503 and miRNA-138 may be used to identify obesity-induced and non-obesity-induced DM; another study showed that miR-143, miR-802, and miR-200a/b/c may cause DM through acting on mTORC2, GSK, and miR-103, miR-107, miR-221 and miR-223 may regulate PI3K-mTOR signaling pathway and cause DM to occur ([@B5]; [@B6]; [@B16]; [@B1]). A preliminary study of our clinical sample found that the plasma miRNA-126 expression level in DM patients was significantly higher than that in the control group. The miRNA-126 expression in the DM group plasma was \~60 times higher than that in the control group. The 28-3p expression level in plasma of DM patients was about 230 times higher than that of the control group. This result suggests that miRNA-126 and miRNA-28-3p are significantly differently expressed in plasma of DM patients, and the expression of circulating miRNA-126 and miRNA-28-3p is positively correlated in the plasma of DM patients (Pearson correlation coefficient is 0.443), suggesting that miRNA-126 and miRNA-28-3p may be involved in the pathogenesis of DM.

With regard to the diagnosis of DM, the diagnosis is mainly based on the measurement of fasting blood glucose and postprandial blood glucose. However, there are many factors that interfere with blood glucose and are easily affected by the patient's physical condition and diet. Therefore, it is necessary to actively explore other methods of diagnosis and treatment. We performed a ROC curve analysis of miRNA-126 and miRNA-28-3p in the plasma of two groups of patients and found that the AUC of miRNA-126 ROC was 0.993, and the cut-off value was 0.01124 with high sensitivity. 96.25%, specificity as high as 98.75%; AUC of miRNA-28-3p ROC was 0.998, when its cut-off value was 0.002038, its sensitivity was as high as 98.75%, and the specificity was as high as 97.50%, the results suggest that both miRNA-126 and miRNA-28-3p can be used as new biomarkers for potential clinical diagnosis of DM, and have higher sensitivity and specificity, providing a new approach for the diagnosis and treatment of DM.

In the final analysis, miRNA research still stays on the level of functional research. We first used bioinformatics analysis to find that both miRNA-126 and miRNA-28-3p may be involved in the insulin signaling pathway and the IGF signaling pathway (insulin/IGF pathway) and MAPK signaling pathways, and it can be speculated that miRNA-126 and miRNA-28-3p may cause DM through regulation of insulin signaling pathways and other related signaling pathways and target genes. Of course, this requires further functional testing and authenticating. Studies have shown that miRNAs interact with lncRNAs and circRNAs, etc. ([@B29]; [@B23]; [@B12]; [@B26]), especially circRNAs, because of their high stability and specific expression ability, their research prospects are considerable, therefore, if combined miRNA, lncRNA, the research on the three circRNAs can provide a deeper understanding of the mechanism of disease and provide a better way for disease prevention and treatment. We found through bioinformatics analysis that both miRNA-126 and miRNA-28-3p regulate lncRNA-XIST and are associated with multiple circRNAs.

Conclusion {#S5}
==========

In summary, both miRNA-126 and miRNA-28-3p may be involved in the pathogenesis of DM, and may serve as a novel biomarker for clinical diagnosis of DM. The main mechanism may be through regulation of insulin signaling pathway and insulin growth factor signaling pathway, and may be related to lncRNAs such as XIST and various circRNAs.
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